一步法核酸扩增在结直肠癌淋巴结转移检测中的作用。

Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection.

机构信息

Division of General and Surgical Oncology, St. Giuseppe Moscati Hospital, Center of National Excellence and High Specialty, Avellino 83100, Italy.

Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States.

出版信息

World J Gastroenterol. 2022 Aug 14;28(30):4019-4043. doi: 10.3748/wjg.v28.i30.4019.

Abstract

Current histopathological staging procedures in colorectal cancer (CRC) depend on midline division of the lymph nodes (LNs) with one section of hematoxylin and eosin staining. Cancer cells outside this transection line may be missed, which could lead to understaging of Union for International Cancer Control Stage II high-risk patients. The one-step nucleic acid amplification (OSNA) assay has emerged as a rapid molecular diagnostic tool for LN metastases detection. It is a molecular technique that can analyze the entire LN tissue using a reverse-transcriptase loop-mediated isothermal amplification reaction to detect tumor-specific cytokeratin 19 mRNA. Our findings suggest that the OSNA assay has a high diagnostic accuracy in detecting metastatic LNs in CRC and a high negative predictive value. OSNA is a standardized, observer-independent technique, which may lead to more accurate staging. It has been suggested that in stage II CRC, the upstaging can reach 25% and these patients can access postoperative adjuvant chemotherapy. Moreover, intraoperative OSNA sentinel node evaluation may allow early CRC to be treated with organ-preserving surgery, while in more advanced-stage disease, a tailored lymphadenectomy can be performed considering the presence of aberrant lymphatic drainage and skip metastases.

摘要

目前,结直肠癌(CRC)的组织病理学分期程序依赖于对淋巴结(LNs)的中线划分,其中一个部分进行苏木精和伊红染色。这条横切线以外的癌细胞可能会被遗漏,这可能导致国际癌症控制联盟(UICC)II 期高危患者的分期不足。一步式核酸扩增(OSNA)检测已成为一种用于检测淋巴结转移的快速分子诊断工具。这是一种分子技术,可以使用逆转录环介导的等温扩增反应来分析整个淋巴结组织,以检测肿瘤特异性细胞角蛋白 19 mRNA。我们的研究结果表明,OSNA 检测在检测 CRC 中的转移性淋巴结方面具有较高的诊断准确性和较高的阴性预测值。OSNA 是一种标准化、观察者独立的技术,可能会导致更准确的分期。有人建议,在 II 期 CRC 中,升级分期可达到 25%,这些患者可以接受术后辅助化疗。此外,术中 OSNA 前哨淋巴结评估可以使早期 CRC 接受保留器官的手术治疗,而在更晚期的疾病中,可以根据异常淋巴引流和跳跃转移的存在进行定制的淋巴结切除术。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索